Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term inhaled dry powder mannitol in cystic fibrosis – safety and efficacy
2006-004078-28Phase 3Terminated
- Sponsor
- Pharmaxis
- Start
- Feb 2012
- Modality
- Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised trial of Bronchitol in cystic fibrosis (CF) (2 arms), sponsored by Pharmaxis. Primary endpoint: Change in absolute FEV1. Started Feb 2012; status: terminated.
02
Drugs
Bronchitol
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2006-004078-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004078-28.